TriangleNCT03206970 · OUTCOME
Time To Response
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEAN
- Unit
- months
- Interval / dispersion
- Standard Deviation
- Time frame
- Up to 3 years and 6 months
What was measured
Time to response was defined as the time from treatment initiation to the first documentation of response.
Analysis population: Safety Analysis Set: All participants who received any dose of study drug.
Groups in this outcome
Zanubrutinib
Zanubrutinib (160 mg) administered BID until disease progression, unacceptable toxicity or death, withdrawal of consent, lost to follow up, or study termination by sponsor, which comes first.
| Group | Source count |
|---|---|
| Zanubrutinib | 72 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Zanubrutinib | 2.72 | 0.105 | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- spread
- 0.105
- value
- 2.72
- denoms
- counts
- group Id
- OG000
- value
- 72
- units
- Participants
- description
- Time to response was defined as the time from treatment initiation to the first documentation of response.
- dispersion Type
- Standard Deviation
- groups
- description
- Zanubrutinib (160 mg) administered BID until disease progression, unacceptable toxicity or death, withdrawal of consent, lost to follow up, or study termination by sponsor, which comes first.
- id
- OG000
- title
- Zanubrutinib
- param Type
- MEAN
- population Description
- Safety Analysis Set: All participants who received any dose of study drug.
- reporting Status
- POSTED
- time Frame
- Up to 3 years and 6 months
- title
- Time To Response
- type
- SECONDARY
- unit Of Measure
- months
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice